Compass Pathways (NASDAQ:CMPS) Upgraded to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Compass Pathways (NASDAQ:CMPS) from a strong sell rating to a sell rating in a research report report published on Tuesday morning,Wall Street Zen reports.

Other equities analysts also recently issued research reports about the stock. BTIG Research increased their price target on shares of Compass Pathways from $14.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, July 7th. Maxim Group boosted their price objective on shares of Compass Pathways from $12.00 to $20.00 and gave the stock a “buy” rating in a report on Friday, May 15th. Compass Point set a $25.00 price objective on shares of Compass Pathways in a report on Tuesday, July 7th. Wolfe Research restated an “outperform” rating on shares of Compass Pathways in a research report on Tuesday, July 7th. Finally, UBS Group set a $18.00 target price on shares of Compass Pathways in a report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Compass Pathways currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.36.

Compass Pathways Stock Down 2.0%

CMPS opened at $13.24 on Tuesday. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.30 and a quick ratio of 1.30. Compass Pathways has a 12 month low of $4.40 and a 12 month high of $15.40. The stock has a market capitalization of $1.83 billion, a P/E ratio of -2.87 and a beta of 2.54. The business has a 50 day simple moving average of $13.12 and a 200-day simple moving average of $10.21.

Compass Pathways (NASDAQ:CMPS) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($1.49). On average, equities analysts anticipate that Compass Pathways will post -1.26 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Ancora Advisors LLC purchased a new stake in shares of Compass Pathways in the 2nd quarter worth about $43,000. EverSource Wealth Advisors LLC grew its stake in Compass Pathways by 67.7% in the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock valued at $26,000 after acquiring an additional 1,920 shares during the last quarter. Persistent Asset Partners Ltd purchased a new position in Compass Pathways during the 4th quarter valued at about $38,000. Caitong International Asset Management Co. Ltd purchased a new position in Compass Pathways during the 4th quarter valued at about $47,000. Finally, Advisory Services Network LLC acquired a new position in Compass Pathways during the third quarter worth about $41,000. Hedge funds and other institutional investors own 46.19% of the company’s stock.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.